ARVN (Arvinas) Research & Development: $254.70 Mil (TTM As of Mar. 2026)


ARVN Arvinas Inc ARVN
70 GF Score
Price $8.12
GF Value $11.82
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Arvinas Research & Development?

Arvinas ARVN +1.25% 70 Research & Development is $254.70 Mil as of Mar. 2026. GuruFocus rates ARVN with a GF Score™ of 70/100 and a GF Value™ of $11.82 (Possible Value Trap). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Arvinas's Research & Development for the three months ended in Mar. 2026 was $60.30 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $254.70 Mil.

Arvinas  (NAS:ARVN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Arvinas Research & Development Related Terms

Arvinas Research & Development Historical Data

* Premium members only.

The historical data trend for Arvinas's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arvinas Research & Development Chart

Arvinas Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 180.40 315.00 379.70 348.20 285.20

Arvinas Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.80 68.60 64.70 61.10 60.30
ARVN
70GF Score
Arvinas Inc ARVN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arvinas Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $254.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $254.70 Mil mean?
Arvinas (ARVN) has a Research & Development of $254.70 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Arvinas and its competitors.
Is Arvinas' Research & Development too high?
Arvinas' current Research & Development is $254.70 Mil. Overall, Arvinas has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arvinas' Research & Development compare to EIKN and GYRE?
Arvinas' Research & Development of $254.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Arvinas and its competitors. Arvinas's current Research & Development is $254.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arvinas stock overvalued right now?
Based on GuruFocus' analysis, Arvinas (ARVN) is currently considered Possible Value Trap. The stock's GF Value™ is $11.82, compared to a current price of $8.12 — trading 31.3% below its estimated fair value. The current Research & Development is $254.70 Mil. Arvinas' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Arvinas (ARVN), the current Research & Development is $254.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arvinas (ARVN) Overvalued in 2026?

Based on GuruFocus' analysis, Arvinas stock appears to be undervalued. The current stock price of $8.12 is trading 31.3% below its estimated GF Value™ of $11.82. GuruFocus considers Arvinas to be Possible Value Trap.

Key valuation signals for ARVN:

  • Research & Development: $254.70 Mil
  • GF Value™: $11.82 vs. price of $8.12 (31.3% below fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the ARVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arvinas Business Description

Address 395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
70GF Score

Get the complete analysis for ARVN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.12
Price
$11.82
GF Value